FRANKLIN LAKES, N.J.,June 02, 2015 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its participation in the White House Forum on Antibiotic Stewardship and outlined multiple steps the company will take to help combat drug resistant organisms.
“BD has a full range of expertise related to identification and prevention of antimicrobial resistance from diagnosis and treatment information to electronic surveillance and prevention of health care associated infections,” said Vincent A. Forlenza, chairman, CEO and president of BD. “We are committed to being a key contributor to this collaborative effort to stop the rise of antibiotic resistant organisms.”
The event brings together key Federal and private sector participants involved in the development, promotion and implementation of antibiotic stewardship activities to ensure the responsible use of antibiotics nationwide.
In support of the Forum, BD outlined multiple actions it plans to take over the next five years to help combat drug resistant organisms and further promote antimicrobial stewardship. Among those commitments include:
- Improve Diagnosis and Treatment
- Develop a new diagnostic test to rapidly detect Carbapenem Resistant Enterobacteriaceae (CRE)
- Create a pandemic sentinel system that includes identification of CRE cases to enable timely intervention
- Deploy antimicrobial susceptibility tests (AST) to ensure the appropriate use of all available antibiotics
- Expand Electronic Surveillance
- Assist health care providers with monitoring and reporting emerging pathogens and antibiotic resistance trends
- Support public health efforts to identify likely HAIs through electronic surveillance surrogate markers, such as the MedMined® NIM (nosocomial infection marker) and improve tracking of antibiotic use
- Reduce HAIs
- Continue research and development into skin antiseptics and needleless connectors to reduce the risks of HAIs
Last year, President Obama signed an Executive Order launching Federal efforts to combat the rise in antibiotic-resistant bacteria. The Administration also issued its National Strategy on Combating Antibiotic-Resistant Bacteria, which outlines steps the U.S. government will take to improve prevention, detection and control of resistant pathogens. Earlier this year, the White House released its National Action Plan to Combat Antibiotic-Resistant Bacteria, a comprehensive effort that identifies critical actions to be taken by government over the next five years. In addition, the President’s FY 2016 Budget proposed nearly doubling the amount of Federal funding for combating and preventing antibiotic resistance to more than $1.2 billion.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com